Vehicle effect on in-vitro and in-vivo performance of spray-dried dispersions

J Pharm Sci. 2025 Jan;114(1):566-576. doi: 10.1016/j.xphs.2024.10.043. Epub 2024 Oct 31.

Abstract

In early drug development, amorphous spray-dried dispersions (SDDs) applied to enhance the bioavailability of poorly water-soluble compounds are typically administered to preclinical species via oral gavage in the form of suspensions. The liquid formulations are usually prepared on the same day of dosing to minimize the exposure of the amorphous material to the aqueous vehicle, thereby reducing the risk of crystallization. Dose-ability (e.g. syringe-ability) of the suspensions is also a critical factor for the administration, particularly when high doses, thus concentrations, are required for toxicology studies. As a result, it is standard practice during early formulation screening to assess the stability and the maximum feasible concentration of SDDs in various vehicles. In this study, we evaluated the impact of different vehicles on the performance of a model SDD in-vitro and in-vivo settings, to mitigate the risks associated with its administration in liquid form. A poorly water-soluble compound (GEN-A) was selected to screen various SDDs and generate the SDD model at 30 % drug load with HPMCAS-MF polymer carrier. The SDD was suspended in selected aqueous vehicles after a careful vehicle components screening, that included suspending agents (HPC-SL), solubilizers (PEG400, Propylene glycol), surfactants (Vitamin E TPGS, SLS, Tween 80, Poloxamer 188), and complexing agents (HP-β-CD, SBE-β-CD). The suspensions were characterized for stability, dose-ability and dissolution in biorelevant media, prior administration in pre-clinical species. The SDD dissolution profile revealed that the drug's supersaturation level was positively impacted by the presence of a surfactant (SLS) and a complexing agent (SBE-β-CD) with respect to a suspending agents (HPC-SL) in the vehicle. Similarly, the pharmacokinetics profiles of the drug following the administration of the SDD in a vehicle with a complexing agent (SBE-β-CD) achieved greater exposure compare to the SDD in a vehicle with a suspending agent (HPC-SL). These findings confirm a synergistic effect between the SDD and the vehicles, suggesting that this combination could be leveraged to maximize the advantages of the amorphous approach.

Keywords: Amorphous Solid Dispersion; Dissolution; Solubility; Spray-Dried Dispersion; Stability; Suspension; Vehicle.

MeSH terms

  • Administration, Oral
  • Animals
  • Biological Availability
  • Chemistry, Pharmaceutical / methods
  • Drug Carriers / chemistry
  • Drug Compounding / methods
  • Drug Stability
  • Excipients / chemistry
  • Male
  • Pharmaceutical Vehicles* / chemistry
  • Polyethylene Glycols / chemistry
  • Propylene Glycol / chemistry
  • Solubility*
  • Spray Drying
  • Surface-Active Agents / chemistry
  • Suspensions
  • Vitamin E / chemistry

Substances

  • Pharmaceutical Vehicles
  • Surface-Active Agents
  • Suspensions
  • Excipients
  • Polyethylene Glycols
  • Vitamin E
  • Propylene Glycol
  • Drug Carriers